BioCentury
ARTICLE | Company News

EMA accepts vintafolide, etarfolatide MAAs

November 29, 2012 1:57 AM UTC

Endocyte Inc. (NASDAQ:ECYT) and partner Merck & Co. Inc. (NYSE:MRK) said EMA accepted for review MAAs for conditional approval of vintafolide and companion diagnostic etarfolatide to treat folate receptor-positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin. The partners said the applications were based on the results from two single-arm Phase II trials in ovarian cancer and non-small cell lung cancer and the Phase IIb PRECEDENT trial in patients with platinum-resistant ovarian cancer. EMA's acceptance of the MAAs triggers a $5 million milestone payment from Merck to Endocyte, which was up $0.07 to $9.08 on Wednesday. ...